What is the role (if any) for Rituximab in a patient with CD20+, Philadelphia chromosome positive ALL?

There are no good randomized data in PH+ disease, but the incorporation of rituximab for CD20+ and PH+ ALL has been standard practice on MD Anderson trials of HyperCVAD+TKI. The challenge has been more on the insurance side - but our approach is to include it if approved.